Enhancing accessibility to the dementia risk profile (DRP) and knowledge of dementia risk reduction (KoDeRR) measuring tools to diverse communities through translation and adaptation in the Nepali language.

Dementia is one of the fastest emerging global public health concerns today, as the World Health Organisation has predicted that the number of cases will triple from 55 million in 2023 to 152 million by 2050. Current evidence indicates that approximately 45% of dementia cases can be prevented or delayed by acting on potentially modifiable risk factors. However, public knowledge regarding this remains unknown in numerous poorly resourced countries, including Nepal, where the prevalence of dementia continues to increase.

ISLAND Campus: a fee-free formal university educational intervention in mid- to later-life to reduce modifiable risk factors for dementia and improve cognition.

Introduction: Previous research has tended to focus on early-life education for dementia risk reduction, yet there are great gains for building cognitive reserve in mid- to later-life through educational interventions. ISLAND (Island Study Linking Ageing and Neurodegenerative Disease) Campus offered free university study to all ISLAND participants, with flexible in-person/online learning models to remove educational, socioeconomic and geographical barriers. Here the core hypothesis of ISLAND Campus was investigated: that engagement in later life education leads to improvements in modifiable risk factors for dementia, cognition and blood-based biomarkers.

Benefit of using an assistive listening device in a hospital setting.

High levels of noise in hospital settings can make communication difficult, especially for older adults. Assistive Listening Devices (ALDs) are personal amplifiers that can improve hearing in background noise. This study investigated the impact of providing ALDs to hospitalized patients 60 years of age and older without using hearing screenings to determine eligibility.

Synthesis of aromatic glycoconjugates as anti-fungal agents against Candida spp. and assessment of their covalent crosslinking capabilities.

Covalent drugs are becoming increasingly attractive in drug discovery, as they can enhance potency and selectivity for their molecular targets. Covalent inhibitors have been investigated for several therapeutic applications, including anti-cancer and anti-infection agents. However, there are only a few examples of covalent inhibitors targeting fungal pathogens.